This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Sarpogrelate
Accession Number
DB12163
Type
Small Molecule
Groups
Investigational
Description

Sarpogrelate has been investigated for the treatment of Diabetes Mellitus, Diabetic Nephropathy, Coronary Artery Disease, and Renal Insufficiency, Chronic.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Sarpogrelate HydrochlorideFQN8N8QP1B135159-51-2POQBIDFFYCYHOB-UHFFFAOYSA-N
Categories
UNII
19P708E787
CAS number
125926-17-2
Weight
Average: 429.513
Monoisotopic: 429.215137722
Chemical Formula
C24H31NO6
InChI Key
FFYNAVGJSYHHFO-UHFFFAOYSA-N
InChI
InChI=1S/C24H31NO6/c1-25(2)16-21(31-24(28)14-13-23(26)27)17-30-22-10-5-4-8-19(22)12-11-18-7-6-9-20(15-18)29-3/h4-10,15,21H,11-14,16-17H2,1-3H3,(H,26,27)
IUPAC Name
4-{[1-(dimethylamino)-3-{2-[2-(3-methoxyphenyl)ethyl]phenoxy}propan-2-yl]oxy}-4-oxobutanoic acid
SMILES
COC1=CC(CCC2=CC=CC=C2OCC(CN(C)C)OC(=O)CCC(O)=O)=CC=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
U5-hydroxytryptamine receptor 2CNot AvailableHuman
U5-hydroxytryptamine receptor 2A
inverse agonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with (S)-Warfarin.
4-hydroxycoumarinThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with 4-hydroxycoumarin.
AbciximabSarpogrelate may increase the anticoagulant activities of Abciximab.
AcenocoumarolThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Acenocoumarol.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Sarpogrelate.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Acetylsalicylic acid.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Sarpogrelate.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Sarpogrelate.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Sarpogrelate.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
5160
PubChem Substance
347828455
ChemSpider
4976
BindingDB
50093789
ChEBI
135697
ChEMBL
CHEMBL52939
Wikipedia
Sarpogrelate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHigh Blood Pressure (Hypertension) / Peripheral Artery Disease (PAD)1
3CompletedPreventionCerebral Infarctions1
3CompletedTreatmentCoronary Artery Disease / Diabetes Mellitus (DM) / Renal Insufficiency,Chronic1
4CompletedTreatmentCoronary Artery Disease1
4RecruitingTreatmentAngina, Prinzmetal's1
4Unknown StatusPreventionChronic Kidney Disease (CKD)1
4Unknown StatusTreatmentDiabetic Nephropathies1
Not AvailableUnknown StatusTreatmentAtherosclerosis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0109 mg/mLALOGPS
logP3.57ALOGPS
logP1.12ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)3.78ChemAxon
pKa (Strongest Basic)8.15ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area85.3 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity117.35 m3·mol-1ChemAxon
Polarizability46.89 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Stilbenes
Sub Class
Not Available
Direct Parent
Stilbenes
Alternative Parents
Phenoxy compounds / Methoxybenzenes / Anisoles / Fatty acid esters / Alkyl aryl ethers / Dicarboxylic acids and derivatives / Trialkylamines / Carboxylic acid esters / Amino acids / Carboxylic acids
show 4 more
Substituents
Stilbene / Phenoxy compound / Anisole / Methoxybenzene / Phenol ether / Alkyl aryl ether / Fatty acid ester / Monocyclic benzene moiety / Fatty acyl / Benzenoid
show 19 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Muntasir HA, Takahashi J, Rashid M, Ahmed M, Komiyama T, Hossain M, Kawakami J, Nashimoto M, Nagatomo T: Site-directed mutagenesis of the serotonin 5-Hydroxytryptamine2c receptor: identification of amino acids responsible for sarpogrelate binding. Biol Pharm Bull. 2006 Aug;29(8):1645-50. [PubMed:16880620]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inverse agonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Muntasir HA, Bhuiyan MA, Ishiguro M, Ozaki M, Nagatomo T: Inverse agonist activity of sarpogrelate, a selective 5-HT2A-receptor antagonist, at the constitutively active human 5-HT2A receptor. J Pharmacol Sci. 2006 Oct;102(2):189-95. Epub 2006 Oct 7. [PubMed:17031071]
  2. Aly SA, Hossain M, Bhuiyan MA, Nakamura T, Nagatomo T: Assessment of binding affinity to 5-hydroxytryptamine 2A (5-HT2A) receptor and inverse agonist activity of naftidrofuryl: comparison with those of sarpogrelate. J Pharmacol Sci. 2009 Aug;110(4):445-50. [PubMed:19672037]

Drug created on October 20, 2016 15:30 / Updated on October 01, 2018 16:48